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Abstract
Background: Current risk stratification in endometrial cancer (EC) results in frequent over- and underuse of adjuvant 
therapy, and may be improved by novel biomarkers. We examined whether POLE proofreading mutations, recently reported 
in about 7% of ECs, predict prognosis.
Methods: We performed targeted POLE sequencing in ECs from the PORTEC-1 and -2 trials (n = 788), and analyzed clinical 
outcome according to POLE status. We combined these results with those from three additional series (n = 628) by meta-
analysis to generate multivariable-adjusted, pooled hazard ratios (HRs) for recurrence-free survival (RFS) and cancer-specific 
survival (CSS) of POLE-mutant ECs. All statistical tests were two-sided.
Results: POLE mutations were detected in 48 of 788 (6.1%) ECs from PORTEC-1 and-2 and were associated with high tumor 
grade (P < .001). Women with POLE-mutant ECs had fewer recurrences (6.2% vs 14.1%) and EC deaths (2.3% vs 9.7%), though, 
in the total PORTEC cohort, differences in RFS and CSS were not statistically significant (multivariable-adjusted HR = 0.43, 
95% CI = 0.13 to 1.37, P = .15; HR = 0.19, 95% CI = 0.03 to 1.44, P = .11 respectively). However, of 109 grade 3 tumors, 0 of 15 
POLE-mutant ECs recurred, compared with 29 of 94 (30.9%) POLE wild-type cancers; reflected in statistically significantly 
greater RFS (multivariable-adjusted HR = 0.11, 95% CI = 0.001 to 0.84, P = .03). In the additional series, there were no EC-
related events in any of 33 POLE-mutant ECs, resulting in a multivariable-adjusted, pooled HR of 0.33 for RFS (95% CI = 0.12 
to 0.91, P = .03) and 0.26 for CSS (95% CI = 0.06 to 1.08, P = .06).
Conclusion: POLE proofreading mutations predict favorable EC prognosis, independently of other clinicopathological 
variables, with the greatest effect seen in high-grade tumors. This novel biomarker may help to reduce overtreatment in EC.
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Endometrial cancer (EC) is the commonest gynecological malig-
nancy in the Western world, and is rising in incidence because of 
increasing obesity and ageing of the population (1). Most cases 
(80%) are detected at an early stage (FIGO stage I) (2) because 
of early symptoms. The standard management of EC consists 
of hysterectomy and bilateral salpingo-oophorectomy with or 
without postoperative vaginal brachytherapy (VBT) or pelvic 
external beam radiotherapy (EBRT) depending on recurrence 
risk (3,4). Women with grade 3 cancers or advanced disease are 
increasingly treated with adjuvant chemotherapy (5,6), the role 
of which will be further defined by ongoing studies. Current risk 
stratification is based on both clinical (age) and pathologic fac-
tors (FIGO stage, tumor type, grade, and lymphovascular space 
invasion [LVSI]). Despite refinement in the use of postoperative 
treatment in EC over the last two decades, over- and underusage 
of adjuvant therapy remains a clinical problem. Approximately 
seven patients with stage I EC with risk factors need to receive 
VBT to prevent one recurrence, while 8% to 10% patients develop 
distant metastases that may have been prevented with adjuvant 
chemotherapy (3–6). Consequently, the identification of molecu-
lar markers predictive of recurrence risk or treatment benefit 
beyond current clinicopathological factors would represent a 
major advance (7). While studies have investigated the prog-
nostic significance of several molecular alterations involved in 
endometrial carcinogenesis, including microsatellite instability 
(MSI), PIK3CA and TP53 mutation (8,9), to date none have been 
incorporated into routine clinical practice.
We recently showed that germline variants in the exonucle-
ase domain of the DNA polymerases POLE and POLD1 predispose 
to cancer, including EC, by impairing polymerase proofreading 
and greatly increasing the rate of base substitution mutations 
(10). We subsequently demonstrated that somatic POLE proof-
reading mutations are found in about 7% of sporadic ECs, where 
they strongly associate with high tumor grade (11). Similar find-
ings have been reported in parallel by The Cancer Genome Atlas 
(TCGA), which also demonstrated that while POLE mutations 
were only found in endometrioid tumors, they were not inversely 
associated with TP53 mutation (12). These pathogenic POLE proof-
reading mutations, about 90% of which cluster in exons 9 and 13, 
localize to amino acids within, or close to, conserved motifs essen-
tial for proofreading function (11,12). In keeping with this, POLE 
proofreading-mutant ECs are ultramutated, with a base substitu-
tion mutation frequency among the highest in human tumors (13).
Different forms of genomic instability in cancers are known 
to be associated with clinicopathological features, including 
prognosis (14–16). Favorable outcome of women with POLE-
mutant ECs has been suggested (12), but only reached statis-
tical significance when limited to analysis of grade 3 tumors 
in a recent report (17), and current evidence is insufficient to 
inform practice (18). In this study, we have analyzed associa-
tions between POLE proofreading mutations, recurrence-free 
and cancer-specific survival in two large, randomized con-
trolled trials (PORTEC-1 and -2) (3,4) of early-stage (FIGO stage 
I), (high-) intermediate risk EC, with central pathology review 
and mature follow-up data, and in three additional smaller EC 
series (9,12,19).
Methods
PORTEC Study Details
Details of the PORTEC-1 and PORTEC-2 studies have been 
published previously (see the Supplementary Materials, avail-
able online) (3,4). PORTEC-1 compared pelvic EBRT with no 
additional treatment (NAT) in 715 women with intermediate 
risk, stage I EC recruited between June 1990 and December 1997 
(3). PORTEC-2 randomly assigned 427 women with high-inter-
mediate risk stage I/IIA EC between May 2002 and September 
2006 to either EBRT or VBT following surgery (4). The median 
(range) duration of follow-up was 159.6 (33.6–222) months in 
PORTEC-1 and 89 (18–122) months in PORTEC-2. The PORTEC 
study protocols were approved by the Dutch Cancer Society and 
by the medical ethics committees at participating centers. All 
patients provided written informed consent to study participa-
tion and treatment.
Additional EC Series
The Leuven (n  =  187) (9), Zurich/Basel (n  =  267) (19), and 
TCGA (n = 373) (12) series have also been reported previously 
(Supplementary Materials, available online). The Leuven and 
TCGA cohorts were collected prospectively, while Zurich/Basel 
cases were identified retrospectively. These sets included 
both endometrioid and nonendometrioid ECs (EECs and 
NEECs), and also included patients with stage III/IV disease 
(21.8–31.2%). Central pathology review was mandated in both 
TCGA and the Zurich/Basel cohorts, while the Leuven cases 
were reviewed by a single academic pathologist. Patients in 
the Leuven and Zurich/Basel cohorts were managed according 
to standard protocols, while treatment in the TCGA series was 
at the discretion of the attending physician: median (range) 
follow-up in each was 29 (1–184) months, 46 (1–173) months, 
and 28.7 (0.6–185.6) months, respectively. Follow-up data var-
ied between series. RFS data were available for the Leuven 
and TCGA series, but not the Zurich/Basel set, while CSS data 
were available for the Leuven and the Zurich/Basel series, but 
absent from the TCGA study. Collection and analysis of the 
Leuven and Zurich/Basel series were approved by the scien-
tific ethics committee from all centers (UZ Leuven Medical 
ethics committee and KEK-ZH-NR: 2010-0358, respectively). 
Ethical approval for anonymized tumor molecular analysis 
was granted by Oxfordshire Research Ethics Committee B 
(Approval No. 05\Q1605\66).
Demographic and Clinicopathological Variables
Baseline demographic and clinicopathological variables were 
treated as either categorical (eg, grade, stage, EEC vs NEEC) or 
continuous (age) as appropriate. All analyses were based on data 
from central pathology review.
Molecular Analysis
Tumor DNA was extracted from formalin-fixed, paraffin-embed-
ded (FFPE) blocks from 434 (60.1%) and 398 (93.2%) ECs from the 
PORTEC-1 and -2 studies, respectively. There were no statistically 
significant differences between the biomarker and the total study 
populations in demographic/clinicopathological characteristics, 
treatment or survival. DNA was extracted from 187 fresh-frozen 
ECs in the Leuven set, 373 fresh-frozen ECs in the TCGA set, and 
260 FFPE ECs in the Zurich/Basel set (Supplementary Methods, 
available online). The Leuven, Zurich/Basel, and TCGA biomarker 
cohorts were similar to the total series population in each case 
(Supplementary Methods, available online).
Sanger sequencing of POLE exons 9 and 13 (Supplementary 
Table 1, available online) was successful in over 94% of cases. For 
TCGA, we extracted POLE mutation data from publicly available 
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whole-exome sequencing data (https://tcga-data.nci.nih.gov/
tcga/) (12). We defined pathogenic POLE proofreading mutations 
as variants absent from public germline sequence databases 
(http://evsgs.washington.edu/EVS/; http://www.1000genomes.
org/) and previously confirmed as somatic variants associated 
with tumor ultramutation (11,12,20,21), with the exception of 
one novel variant predicted to perturb protein function by SIFT 
(http://sift.jcvi.org) and Mutation Assessor (http://mutationasses-
sor.org). All variants were confirmed in at least duplicate inde-
pendent polymerase chain reaction and sequencing reactions.
Statistical Analysis
Analyses performed and reported in this biomarker study are 
listed in Supplementary Table 2 (available online) in accordance 
with published guidelines (22,23). For analysis of the association 
of POLE mutation with outcome, our primary endpoint was recur-
rence-free survival (RFS), with secondary endpoints of cancer-
specific survival (CSS), and overall survival (OS). In the PORTEC 
studies, RFS was defined as the time from random assignment 
to relapse, with censoring at last contact or death in case of no 
recurrence. CSS was measured as the time from random assign-
ment to death from EC, with censoring at date of last contact or 
noncancer death. OS was measured as the time from random 
assignment to death from any cause, with censoring at date of last 
contact in patients still alive. The same criteria were used in the 
additional series, with the exception that survival measurements 
were from time of diagnosis. Survival curves were plotted using 
the Kaplan-Meier method and compared by the log-rank test. We 
used Cox proportional hazards models to calculate hazard ratios 
(HRs) for RFS, CSS, and OS of POLE-mutant ECs relative to POLE 
wild-type tumors by univariable analyses and, following adjust-
ment for baseline characteristics and prognostic factors (age, 
tumor type, grade, LVSI, depth of myometrial invasion, and treat-
ment), by multivariable analyses (see Supplementary Methods 
and Supplementary Tables 3–6, available online). Proportionality 
of hazards in Cox models was confirmed by visual inspection of 
complementary log plots or by interaction terms of covariables 
and (log)time. In view of the similar patient populations, the 
limited number of cancer-related events in both PORTEC trials, 
and the modest frequency of POLE mutations, the PORTEC stud-
ies were combined for most analyses. For Cox regression analy-
sis of the PORTEC grade 3 subset and the Leuven, Zurich/Basel, 
and TCGA series, we applied Firth’s correction (24), owing to the 
absence of events in the POLE-mutant groups. For multivari-
able analysis of the additional series, we included disease stage 
as a covariable; although myometrial invasion, LVSI, and treat-
ment were not included because of lack of data, we confirmed 
that omission of these variables from the PORTEC multivariable 
analyses did not alter estimates of RFS or CSS with POLE mutation 
(P  =  .93 and P  =  .87 respectively) (see Supplementary Methods, 
available online). Statistical analyses were performed using SPSS 
(SPSS Inc., Chicago, IL), Stata (StataCorp, College Station, TX) and R 
(http://www.r-project.org/). All P values were two-sided. A P value 
under .05 was considered statistically significant.
Results
Patient Characteristics and POLE Proofreading 
Mutations in PORTEC Studies
Demographic and clinicopathological characteristics of the 
PORTEC study participants in whom tumor POLE sequencing 
was successful are shown in Table 1. The majority (about 98%) 
of cancers in both studies were EECs. POLE exon 9 and 13 proof-
reading mutations were detected in 48 of 788 (6.1%) tumors from 
the combined PORTEC studies (Table  1), with similar distribu-
tion across study arms (11,12). With the exception of two tumors 
harboring a germline polymorphism of uncertain pathogenic-
ity (rs150032060; c.1282G>A, p.Ala428Thr), detected in tumor-
free myometrium in both cases and excluded from subsequent 
analyses, all mutations were recurrent substitutions at somatic 
mutational hotspot codons (Supplementary Table  7, available 
online) known to cause ultramutation (11,12). Apart from one 
neuroendocrine tumor, all POLE mutations occurred in endome-
trioid ECs. Analysis of 48 available preoperative curettings identi-
fied POLE mutations in all five cases in which they were detected 
in the subsequent hysterectomy, resulting in 100% concord-
ance. Compared with POLE wild-type ECs, POLE-mutant tumors 
occurred in younger women (median age 63.5 vs 68.5 years, P < 
.001, t test), and were more commonly grade 3 (31.3% vs 12.7%, 
P < .001, χ2 test), though LVSI and deep (>50%) myometrial inva-
sion were less frequent (0% vs 9.5%, P = .03, and 58.2% vs 71.9%, 
P = .045, respectively, χ2 test) (Table 1).
Clinical Outcome by POLE Proofreading Mutation in 
PORTEC Studies
We first examined the association of POLE proofreading muta-
tion with EC recurrence. Three of 48 (6.2%) women with POLE-
mutant tumors developed local or distant recurrence during 
study follow-up, compared with 104 of the other 740 (14.1%) 
patients (Figure 1A, Table 2). All three recurrences in the POLE-
mutant cohort were distant metastases without locoregional 
relapse and occurred in women with grade 1 EECs and deep 
myometrial invasion, managed by observation, EBRT, and VBT, 
respectively. The univariable HR for recurrence-free survival 
(RFS) with tumor POLE proofreading mutation was 0.41 (95% 
CI = 0.13 to 1.28, P = .13), with little change following adjustment 
for known prognostic variables by Cox regression (HR  =  0.43, 
95% CI = 0.13 to 1.37, P = .15) (Figure 1A, Table 2; Supplementary 
Tables 3 and 5, available online). As many local EC recurrences 
are salvageable with therapy, we next examined whether cancer-
specific survival (CSS) varied according to tumor POLE mutation. 
In women with POLE-mutant EC, there was one (2.3%) EC death 
during follow-up, compared with 72 (9.7%) in the rest of the study 
population. The unadjusted HR for CSS was 0.20 (95% CI = 0.03 
to 1.46, P  =  .11), with minimal alteration following multivari-
able analysis (HR = 0.19, 95% CI = 0.03 to 1.44, P = .11) (Figure 1B, 
Table 2; Supplementary Tables 4 and 6, available online). Overall 
survival of women with POLE-mutant ECs was not statistically 
significantly greater than that of other patients by univariable 
or multivariable analysis (10-year OS = 76.2% vs 70.4%) (Table 2).
The strong association of POLE mutations with high tumor 
grade (11) caused us to hypothesize that their apparent prognostic 
effect would be most evident in this group, who are commonly 
considered for treatment intensification. Of 109 patients with 
grade 3 tumors, there were no recurrences or cancer deaths in the 
15 (13.7%) POLE-mutant case, compared with 29 (30.9%) relapses 
and 25 (26.6%) EC deaths in the remaining 94 women (Figure 2, A 
and B), reflected in statistically significantly improved RFS in uni-
variable analysis (HR = 0.09, 95% CI = 0.001 to 0.66, P =  .01) and, 
following adjustment for other prognostic variables in multivari-
able analysis (HR = 0.11, 95% CI = 0.001 to 0.84, P = .03) (Table 3; 
Supplementary Tables 8 and 9, available online). These results 
were essentially unchanged after limiting RFS analysis to the 97 
grade 3 endometrioid ECs (univariable HR = 0.11, 95% CI = 0.001 
to 0.78, P =  .02; multivariable-adjusted HR = 0.12, 95% CI = 0.001 
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to 0.87, P = .03) (Supplementary Table 8, available online). Notably, 
POLE proofreading mutation was a stronger predictor of recur-
rence and EC death than all other prognostic variables examined 
in these analyses (Supplementary Tables 8 and 9, available online).
Pooled Analysis With Additional EC Series
While the PORTEC analyses demonstrated a tendency for POLE 
proofreading-mutant ECs of all grades to improved outcome, the 
generally good prognosis of patients limited our ability to con-
firm this beyond the grade 3 subgroup. We therefore sought to 
support our results by analysis of two EC series from Leuven and 
Zurich/Basel, together with the published TCGA set, collectively 
comprising an additional 628 patients.
POLE proofreading mutations were detected in 33 (5.3%) case 
patients in the additional series (Supplementary Table 7, avail-
able online). As in the PORTEC studies, POLE-mutant tumors 
were more frequently high-grade (54.5% vs 32.4%, P  =  .013, χ2 
1 51 050
1· 0
0· 8
0· 6
0· 4
0· 2
0· 0
C
um
ul
at
iv
e 
pr
ob
ab
ilt
y 
of
 re
cu
rr
en
ce
Years since randomization
1 51 050
1· 0
0· 8
0· 6
0· 4
0· 2
0· 0
Years since randomization
A B
Number at risk
POLE wild-type
POLE mutant
740
48
579
40
228
17
36
4
740
48
603
41
277
20
73
7
C
an
ce
r s
pe
ci
fic
 s
ur
vi
va
l
P=.15 P=.11
POLE wild-type
POLE proofreading-mutant
POLE wild-type
POLE proofreading-mutant
Figure 1. Cumulative probability of recurrence (A) and cancer-specific survival (B) according to POLE proofreading mutation in the combined PORTEC studies. P values 
are obtained by two-sided log-rank test.
Table 2. Clinical outcome in PORTEC studies according to POLE proofreading mutation determined by univariable and multivariable analysis
Outcome Events/total (%) 10-year, %
Univariable analysis Multivariable analysis*
HR (95% CI) P† HR (95% CI) P†
Recurrence
 POLE wild-type 104/740 (14.1) 15.2 0.41 (0.13 to 1.28) .13 0.43 (0.13 to 1.37) .15
 POLE mutant‡ 3/48 (6.2)  5.5
Cancer-specific survival
 POLE wild-type 72/740 (9.7) 89.7 0.20 (0.03 to 1.46) .11 0.19 (0.03 to 1.44) .11
 POLE mutant‡ 1/48 (2.3) 97.7
Overall survival
 POLE wild-type 248/740 (33.5) 70.4 0.69 (0.38 to 1.22) .20 1.06 (0.59 to 1.92) .85
 POLE mutant‡ 12/48 (25.0) 76.2
* Multivariable Cox models include POLE mutation, age, nonendometrioid histology, tumor grade, and lymphovascular invasion. CI = confidence interval; HR = hazard 
ratio.
† Calculated using Cox proportional hazards test. All statistical tests were two-sided.
‡ POLE exon 9 or 13 proofreading mutation.
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test) and were generally of endometrioid histology, though three 
POLE-mutant mixed endometrioid/serous and one serous can-
cer were detected in the Leuven series (Supplementary Tables 
10–12, available online).
In the two series with RFS data—Leuven and TCGA—no 
POLE-mutant EC recurred with median follow-up of 28 months, 
compared with 31.6% and 19.0% of other tumors, respectively 
(Supplementary Figures 1A and 2, Supplementary Tables 13 and 
14, available online). Similarly, for the two series in which CSS 
was documented—Leuven and Zurich/Basel (median follow-up 
46  months)—there were no EC deaths in women with POLE-
mutant tumors, compared with 18.6% and 10.8% of the remain-
ing patients (Supplementary Figures 1B and 3, Supplementary 
Tables 13 and 15, available online). As anticipated given their 
sizes, no individual series demonstrated statistically significant 
differences in the RFS/CSS of POLE-mutant ECs by either uni-
variable or multivariable analyses (Supplementary Tables 13–15, 
available online). We therefore combined multivariable-adjusted 
HRs from each series with those from the PORTEC studies by 
meta-analysis to generate pooled estimates for RFS and CSS 
according to POLE proofreading mutation (Figure  3, A and B). 
POLE-mutant ECs were associated with statistically significantly 
greater RFS compared with other tumors (HR = 0.33, 95% CI = 0.12 
to 0.91, P = .03), with no evidence of heterogeneity among stud-
ies (P =  .66), though the difference in CSS was not statistically 
significant using a two-tailed test (HR = 0.26, 95% CI = 0.06 to 
1.08, P  =  .06). Interestingly, the only POLE-mutant tumors that 
recurred were early-stage, grade I ECs from the PORTEC cohorts 
(Supplementary Table 16, available online). To date, most POLE 
proofreading mutations have been detected in EECs (11,12,17), 
although POLE-mutant NEECs have been reported (11,25,26). 
Given the difficulty in histotyping high-grade ECs, we consid-
ered the possibility that the four POLE-mutant tumors reported 
as NEECs in the Leuven series may have been misclassified, thus 
biasing our results because of the poor prognosis of NEEC. We 
therefore confirmed that the estimate of RFS was essentially 
unchanged by repeating the meta-analysis after excluding POLE 
wild-type NEECs from all cohorts (HR = 0.34, 95% CI = 0.12 to 0.93, 
P = .04) (Supplementary Tables 5, 6, 13, and 14, available online).
Discussion
By analyzing tumors from nearly 800 women in two large, ran-
domly assigned controlled trials and pooling data with three 
independent series comprising over 600 additional patients, 
we have demonstrated that POLE proofreading-mutant ECs of 
all grades display excellent prognosis, independent of other 
known prognostic factors. POLE-mutant tumors have a risk of 
recurrence approximately one third that of other ECs, and a rela-
tive risk of cancer death that appears even lower, though the 
latter finding was not statistically significant in our analysis. 
This is despite a strong association of POLE proofreading muta-
tions with high tumor grade—a characteristic that predicts a 
high risk of metastases in early EC (27). Indeed, in the PORTEC 
studies, no POLE-mutant grade 3 EC recurred, compared with 
30.9% of grade 3 tumors in the rest of this subgroup, consistent 
with a recent report, which combined high-grade ECs from the 
TCGA series with an additional, small retrospective series (17). 
The role of adjuvant chemotherapy in patients with high-risk 
grade 3 tumors is currently under investigation, and as systemic 
therapy was not used in PORTEC-1 or -2 these data suggest that 
patients with POLE proofreading-mutant EC may be unlikely to 
benefit from such treatment. Similarly, the absence of locore-
gional recurrence of POLE-mutant ECs was observed across all 
arms of the PORTEC studies, including the NAT arm of PORTEC-1. 
While further studies are required before firm conclusions can 
be drawn on the implications of POLE proofreading mutations 
for postoperative treatment in EC, our results suggest that mini-
mization of adjuvant therapy for POLE-mutant ECs localized to 
the uterus may be worthy of investigation. They also suggest 
POLE proofreading mutation should be considered for inclusion 
in cancer gene panels used in EC, as it may improve prognostica-
tion, particularly for grade 3 tumors.
While highlighting the strengths of using high-quality clini-
cal trial sample banks for biomarker research (18), our study has 
limitations. The challenge of confirming even a strong effect of 
a marker with modest (<10%) frequency in a population with 
relatively favorable prognosis meant that we used additional EC 
series to confirm the improved RFS of POLE-mutant ECs. While 
acknowledging the limitations of sets containing a mixture of 
histological subtypes and stages, with limited follow-up and 
lacking comprehensive treatment data (18) the similar results 
from each following multivariable analysis suggests that our 
results are unlikely to be because of chance or confounding 
by inclusion of NEECs in our analyses. However, as highlighted 
above, it will be important to confirm the favorable prognosis 
of POLE-mutant ECs in further independent series, and particu-
larly in tumors of advanced stages. It should also be noted that 
Table 3. Clinical outcome of patients with grade 3 tumors in PORTEC studies according to POLE proofreading mutation by univariable and 
multivariable analysis
Outcome Events/total 10-year, %
Univariable analysis Multivariable analysis*
HR (95% CI) P† HR (95% CI) P†
Recurrence
 POLE wild-type 29/94 30.8 0.09 (0.001 to 0.66) .01 0.11 (0.001 to 0.84) .03
 POLE mutant‡ 0/15 0
Cancer-specific survival
 POLE wild-type 25/94 73.4 0.11 (0.001 to 0.78) .02 0.14 (0.001 to 1.01) .05
 POLE mutant‡ 0/15 100
Overall survival
 POLE wild-type 46/94 60 0.49 (0.18 to 1.36) .17 0.78 (0.27 to 2.21) .63
 POLE mutant‡ 4/15 73.3
* Multivariable Cox models include POLE mutation, age, nonendometrioid histology, and lymphovascular invasion. CI = confidence interval; HR = hazard ratio.
† Calculated using Cox proportional hazards test with Firth’s correction for analysis of recurrence and cancer-specific survival (because of absence of events in the 
POLE-mutant groups). All statistical tests were two-sided.
‡ POLE exon 9 or 13 proofreading mutation.
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as a single biomarker survey of POLE hotspot exons in ECs of 
predominantly endometrioid histology, we are presently unable 
to determine the effect of the about 10% of pathogenic variants 
outside exons 9 and 13, (11,12) or whether the effect of POLE 
mutation varies according to tumor molecular subtypes. Both 
questions are likely to be addressed by future studies.
POLE proofreading-mutant cancers are a molecularly distinct 
group of tumors with a striking mutation burden and distinctive 
mutation signature (11–13). Whether these characteristics con-
tribute to their favorable prognosis awaits confirmation. Study 
of mutator polymerases in yeast has confirmed the existence of 
a mutational threshold, which, if exceeded, results in decreased 
viability because of lethal mutations in essential genes prior 
to cell division (28). It will be of interest to determine whether 
the dramatic increase in mutation rate in S. cerevisiae caused by 
the corresponding substitution to human POLE p.Pro286Arg (29) 
approaches this error threshold. Similarly, analysis of the bur-
den of deleterious mutations accumulated in POLE proofread-
ing-mutant cancers may provide insights into their behavior 
(30).
Over the last two years, we and others have shown that 
somatic mutations in the proofreading domain of POLE occur in 
several human tumors (10–12,20,31). We now demonstrate that, 
despite a strong association with high grade, POLE proofreading-
mutant ECs have a favorable prognosis. While the frequency 
of POLE mutation in EC is modest, it is worth noting that it is 
broadly similar to that of many novel molecular aberrations 
recently discovered by TCGA and other sequencing efforts. As 
most common cancer variants are currently not actionable, 
similar analyses of these modest-frequency (5% to 10%) molecu-
lar subgroups are likely to be essential if we are to realize the 
ambition of personalized cancer medicine during the next 
decade.
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